Medicare drug coverage

Basaglar: 2027 Medicare Part D coverage

38 of 5,495 Part D plans (1%) list Basaglar on their 2027 formulary, the same share as 2026. 55% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Basaglar is number 72 by total Medicare Part D spending in 2024 ($665 million). Plans that list it most often put it on tier 4. Counts use 3 RxNorm products for this name.

Basaglar Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it49 (1%)38 (1%)no change
Prior authorization (of plans that list it)8 (16%)7 (18%)+2 points
Step therapy (of plans that list it)15 (31%)14 (37%)+6 points
Quantity limit (of plans that list it)0 (0%)0 (0%)no change
Any of the three (of plans that list it)23 (47%)21 (55%)+8 points
Not listed or restricted (of all plans)5,492 (100%)5,478 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Basaglar formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 12 (4%)0 (0%)
Tier 324 (49%)16 (42%)
Tier 423 (47%)21 (55%)
Tier 60 (0%)1 (3%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 0 of them (0%) added prior authorization, step therapy, or a quantity limit for Basaglar, and 2 stopped listing it.

Basaglar: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20272 (0%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier1 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit0 (0%)
Added at least one of the three0 (0%)
Removed at least one of the three0 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Basaglar off the formulary or list it with prior authorization, step therapy, or a quantity limit. Wisconsin ranks first at 100%, with 7% of its plans using prior authorization or step therapy; New Jersey ranks last at 97%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Basaglar, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Wisconsin97100%7%no change
2Alaska9100%0%no change
3Alabama115100%0%no change
4Arkansas86100%0%no change
5Arizona148100%0%no change
6California397100%0%no change
7Colorado106100%0%no change
8Connecticut54100%0%no change
9District of Columbia21100%0%no change
10Delaware43100%0%no change
11Georgia151100%0%no change
12Hawaii50100%0%no change
13Iowa64100%0%no change
14Idaho45100%0%no change
15Illinois133100%0%no change
16Indiana140100%0%no change
17Kansas84100%0%no change
18Kentucky123100%0%no change
19Louisiana126100%0%no change
20Massachusetts92100%0%+2 points
21Maryland49100%0%no change
22Maine52100%0%no change
23Michigan183100%0%no change
24Minnesota63100%0%no change
25Missouri171100%0%no change
26Mississippi105100%0%no change
27Montana27100%0%no change
28North Carolina177100%0%no change
29North Dakota26100%0%no change
30Nebraska51100%0%no change
31New Hampshire25100%0%no change
32New Mexico68100%0%no change
33Nevada100100%0%no change
34New York215100%0%no change
35Ohio173100%0%no change
36Oklahoma81100%0%no change
37Rhode Island29100%0%no change
38South Carolina91100%0%no change
39South Dakota30100%0%no change
40Tennessee157100%0%no change
41Texas412100%0%no change
42Utah53100%0%no change
43Virginia145100%0%no change
44Vermont14100%0%no change
45Washington114100%0%no change
46West Virginia70100%0%no change
47Wyoming13100%0%no change
48Oregon9299%0%no change
49Florida54999%0%+1 point
50Pennsylvania32498%4%no change
51New Jersey7497%3%+2 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Basaglar off or restrict it.

Basaglar coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Lifetime Healthcare, Inc.210%none list it100%no change0
Athena Healthcare Holdings, LLC190%none list it100%no change0
Mitchell Family Office190%none list it100%no change0
Risant Health, Inc.170%none list it100%no change0
Champion Health Plans-USA, LLC.160%none list it100%no change0
MEDICAL MUTUAL OF OHIO160%none list it100%no change0
Ultimate Healthcare Holdings, LLC160%none list it100%no change0
Gold Kidney Health Plan150%none list it100%no change0
Trinity Health Corporation150%none list it100%no change0
CuraCor Solutions Corp.140%none list it100%no change0
Lumeris Group Holdings Corporation140%none list it100%no change0
Rifkin Managed Care Holding, LLC140%none list it100%no change0
Sanford Health140%none list it100%no change0
University of Wisconsin Hospitals and Clincs Autho140%none list it100%no change0
Cambia Health Solutions, Inc.130%none list it100%no change0
Clover Health Holdings, Inc.130%none list it100%no change0
Henry Ford Health System130%none list it100%no change0
Curana Health Holdings, LLC120%none list it100%no change0
Fallon Community Health Plan, Inc.120%none list it100%no change0
Louisiana Health Service & Indemnity Company120%none list it100%no change0
ATRIO Health Plans110%none list it100%no change0
Aware Integrated, Inc.100%none list it100%no change0
Gemstone Holdings, Inc.100%none list it100%no change0
Intermountain Health Care, Inc.100%none list it100%no change0
Thomas Jefferson University10100%0%0%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Basaglar?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Other Insulin Glargine,Hum.Rec.Anlog products

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing